Back to today’s briefing

Story perspectives

ImmunityBio Soars 41.86% After Bladder Cancer Drug Approval

2/19/2026

43 9 Full Breakdown

Summary

Story summary

ImmunityBio (NASDAQ:IBRX) closed at $8.54, up 41.86%, after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer.
Trading volume reached 78.5 million shares, well above the three-month average.
The company reports a 700% rise in Anktiva sales in 2025 and expansion into over 30 countries.
The Motley Fool Stock Advisor does not include ImmunityBio among its top-rated stocks.

1 of 1

Story summary

ImmunityBio (NASDAQ:IBRX) closed at $8.54, up 41.86%, after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer.
Trading volume reached 78.5 million shares, well above the three-month average.
The company reports a 700% rise in Anktiva sales in 2025 and expansion into over 30 countries.
The Motley Fool Stock Advisor does not include ImmunityBio among its top-rated stocks.